Navigation Links
Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions
Date:5/30/2008

CHICAGO, May 30 /PRNewswire/ -- Data from three observational studies reported at the American Society of Clinical Oncology (ASCO) Annual Meeting evaluated transfusion-related outcomes in cancer chemotherapy patients with various hemoglobin (Hb) levels prior to or during administration of erythropoiesis-stimulating agents (ESAs).

Two analyses were conducted using observational data from the Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies (DOSE) Registry. The first study (Larholt et al., abstract number 6637) reported that lower mean Hb levels achieved during ESA therapy were associated with increased transfusion requirements in cancer patients receiving chemotherapy. Another study of oncology patients who initiated ESA therapy at different baseline Hb levels (Burton et al., publication number 20637) concluded that blood utilization was greater when ESA therapy was initiated in patients who had baseline Hb of less than 10 grams per deciliter of blood (g/dL) compared with patients who received ESA therapy with a baseline Hb between 10 and 11 g/dL.

The third study (Gilmore, et al., abstract number 6548) examined hematologic outcomes in ESA-treated cancer chemotherapy patients with chemotherapy-induced anemia before and after implementation of the Centers for Medicare and Medicaid Services (CMS) National Coverage Determination (NCD) for ESAs. The results found lower Hb values and higher transfusion rates in patients covered by Medicare following adoption of the NCD guidelines for reimbursement for ESA therapies.

"As ESA coverage policies have become more restrictive, these findings are important in helping stakeholders understand the potential impact on transfusion patterns. The data demonstrated that when patients achieved lower mean hemoglobin levels during ESA therapy for chemotherapy-induced anemia, the need for transfusions increased," said Kay Larholt, Sc.D., Vice President, Biometrics, at Abt Bio-Pharma Solutions, Inc
'/>"/>

SOURCE Ortho Biotech Products, L.P.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Observational Data Show Transfusion Patterns in Chemotherapy-Induced Anemia Patients Receiving Erythropoiesis-Stimulating Agents
2. Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
3. Genmab Announces Updates on Phase III Cancer Studies
4. Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting
5. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
6. Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting
7. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
8. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
9. Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer
10. New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C)
11. N30 Pharma Announces Completion of Phase 1 Clinical Studies With N30-201
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... The scientific team of a new biotech company ... academics in the field of aging Prof. Robert J. ... for model animals - 10 fold for nematodes) has recently ... primarily, around the stability and stress resistance of certain gene ... analysis of a model gene network links aging, stress resistance, ...
(Date:8/28/2015)... LOS ANGELES , FARUM, Denmark ... -- On July 31, 2015 the US Food ... for the treatment of Major Depressive Disorder in adult patients ... medication in the current episode. TMS is a non-invasive technique ... implicated in patients suffering from Major Depressive Disorder. The procedure ...
(Date:8/28/2015)... y LONDRES, 28 de agosto de ... PHIA) anunció hoy su participación en el  Congreso ... sus soluciones cardiológicas más recientes y novedosas, entre ... que conectan a las personas y la tecnología ... ayudar a diagnosticar, guiar los tratamientos y permitir ...
Breaking Medicine Technology:Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5
... 29, 2011 UBM Canon,s leading brand, Japan Medical Design ... the launch of its new Japanese-language website with enhanced content and ... website allows users to find the resources and information they ... Editor-in-Chief, EMDT , JMDMT , and CMDM ...
... June 29, 2011 Cayenne Medical, Inc., a private ... II Meniscal Repair System, its second generation device for ... on display at the 2011 American Orthopaedic Society for ... CA.   Tal David, MD, orthopedic sports ...
Cached Medicine Technology:UBM Canon Announces New Japanese-Language Website for Japan Medical Design & Manufacturing Technology: www.jmdmt.com 2Cayenne Medical, Inc. Launches CrossFix® II Meniscal Repair System 2
(Date:8/28/2015)... ... 28, 2015 , ... Approximately 2,000 United Methodists are expected ... helping children, a thank you to the many creative and generous ways in ... United Methodist initiative to end malaria deaths. , The Columbus Zoo and Aquarium ...
(Date:8/28/2015)... ... 2015 , ... An article published August 19th by the LA ... through to open a pizzeria in Westchester. Mr. LaRocco was aware from opening prior ... but the current process, having already gone on for over a year, is taking ...
(Date:8/28/2015)... TX (PRWEB) , ... August 28, 2015 , ... For ... Center is taking part with their subsidiary USPI Tenet Health. , The American Heart ... fight heart disease and stroke. They believe that together, a difference can be made. ...
(Date:8/28/2015)... ... August 28, 2015 , ... As reported by Medical Daily ... FDA clearance for results that last for two years, the longest of any cellulite ... who are looking for a long-lasting, effective solution for their cellulite, according to Dr. ...
(Date:8/28/2015)... Michigan (PRWEB) , ... August 28, 2015 , ... On ... Western Michigan, joined as sponsor of the “Music With A Mission” benefit concert in ... behind the event was to raise money to support music education programs in the ...
Breaking Medicine News(10 mins):Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2
... the second year in a row, the American Red Cross and ... their families around the world this holiday season. This year a ... 300 military installations and hospitals around the world. , ... , There are many ways you can ...
... 2007, - ... - Debt financing is ... VANCOUVER, Nov. 26 /PRNewswire-FirstCall/ - CRH Medical Corporation (CRM:TSX-V) announced today ... and unveiled a new strategy designed to mitigate the need to obtain ...
... Streamline Health Solutions, Inc. (Nasdaq: STRM ) ... E. Vick, Jr., as the Company,s interim Chief Financial Officer ... Officer. Mr. Vick may be considered as a candidate ... Chief Financial Officer, Mr. Vick will also continue to serve ...
... Watson Pharmaceuticals,Inc. (NYSE: WPI ... announced,that its subsidiary, Watson Laboratories, Inc., has ... Food and Drug Administration on its Abbreviated,New ... (XL) in the 150 mg strength. ...
... may be affected by phthalates in these products, experts ... exposed to a common hairspray chemical while at work ... an abnormally placed urinary opening, a new report says. ... nail and hair products contain chemicals called phthalates, such ...
... WASHINGTON, Nov. 26 Talk about being a Grinch! On ... of the government workforce -- are having their benefits cut ... , That,s right, BCBS has drastically altered a ... upon for their healthcare coverage -- and hasn,t bothered to ...
Cached Medicine News:Health News:Remember to Send 'Holiday Mail For Heroes' and Thank a Service Member this Thanksgiving 2Health News:CRH Medical reports Q3 2008 results 2Health News:CRH Medical reports Q3 2008 results 3Health News:CRH Medical reports Q3 2008 results 4Health News:CRH Medical reports Q3 2008 results 5Health News:CRH Medical reports Q3 2008 results 6Health News:Streamline Health Announces Appointment of Interim Chief Financial Officer 2Health News:Watson Pharmaceuticals Receives FDA Final Approval for Generic Wellbutrin XL(R) 150 mg 2Health News:Blue Cross/Blue Shield Christmas Gift to Federal Employees: Surprise, We're Cutting Your Benefits!; Patients, Doctors and Health Care Providers Outraged 2
... management software - was designed by ... improvement tool helps diabetes care providers ... bridges medicine with technology by providing ... information technology product. This diabetes ...
... management of diabetes in order to maintain tight ... effective way to reduce or even prevent diabetes-related ... improving a diabetes patients quality of life, however, ... have been the guiding factors in the development ...
... by the CGMS System Gold can assist ... program based on detailed glycemic profiles. Its ... improve motivation and collaboration with patients.1, ... with all diabetes patients, it may be ...
... Biographer is intended for detecting trends and ... (aged 18 and older) and children/adolescents (aged ... supervise the use of the G2 Biographer ... intended to supplement, not replace, conventional blood ...
Medicine Products: